乳腺癌患者血清VEGF-C水平與癌組織C-erbB-2蛋白的表達及臨床意義_《中國普外基礎與臨床雜志》

作者：

黃桂林 ¹ , 侯吉學 ² , 吳毅平 ¹

1.華中科技大學同濟醫學院附屬同濟醫院整形外科（武漢 430030）;;
2.石河子大學醫學院第一附屬醫院胃腸乳腺外科（新疆石河子 832008）;

關鍵詞：

乳腺癌血清血管內皮生長因子C C-erbB-2 鑒別診斷

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討乳腺癌患者血清血管內皮生長因子C (VEGF-C)水平及癌組織中C-erbB-2蛋白表達及其臨床意義。
方法選取女性乳腺浸潤性導管癌患者和乳腺良性病變患者各62例，采用ELISA法檢測患者術前和術后1個月血清VEGF-C水平，免疫組織化學法檢測乳腺癌組織C-erbB-2蛋白表達，分析VEGF-C與乳腺癌臨床病理特征及C-erbB-2蛋白表達的關系。
結果乳腺癌患者術前血清VEGF-C水平為（279.65±17.34） pg/ml，乳腺良性病變患者為（167.26±12.15） pg/ml，兩者比較差異有統計學意義(P＜0.01)。乳腺癌患者術后1個月血清VEGF-C水平為（209.45±15.23） pg/ml，與其術前比較差異有統計學意義(P＜0.01)。VEGF-C水平與原發腫瘤分期有關（P＜0.05），與患者年齡、腫瘤大小、有無淋巴結轉移、絕經情況及ER和PR的表達無關（P gt;0.05）。C-erbB-2蛋白在乳腺癌中的表達陽性率為54.84%（34/62)，明顯高于乳腺良性病變的11.29%（7/62)，P＜0.01。乳腺癌腋窩淋巴結轉移患者的C-erbB-2蛋白表達陽性率(69.44%)明顯高于腋窩淋巴結無轉移患者(34.62%，P＜0.05)。血清VEGF-C水平隨癌組織中C-erbB-2陽性表達強度增強而增高，兩者呈正相關（r=0.813，P＜0.05）。
結論乳腺疾病患者血清中VEGF-C水平可能成為鑒別乳腺良、惡性病變的輔助指標之一； C-erbB-2與乳腺癌淋巴結轉移有關；在乳腺癌的淋巴轉移途徑中VEGF-C可能與C-erbB-2存在著協同作用。

引用本文： 黃桂林,侯吉學,吳毅平. 乳腺癌患者血清VEGF-C水平與癌組織C-erbB-2蛋白的表達及臨床意義. 中國普外基礎與臨床雜志, 2009, 16(7): 514-517. doi: 復制

1.	李樹玲主編. 乳腺腫瘤學 [M]. 第1版. 北京：科學技術文獻出版社， 2000： 392393.
2.	Birner P, Oberhuber G, Satni J, et al. Evaluation of the United States Food and Drug Administrationapproved scoring and test system of HER2 protein expression in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(6): 16691675.
3.	Nathanson SD. Insights into the mechanisms of lymph node metastasis [Ｊ]. Cancer, 2003; 98(2): 413423.
4.	Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma：correlation with clinicopathologic parameters and VEGFfamily gene expression [Ｊ]. Mod Pathol, 2005; 18(1): 143152.
5.	Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factorCmediated lymphangiogenesis promotes tumour metastasis [Ｊ]. EMBO J, 2001; 20(4): 672682.
6.	Bando H, Weich HA, Horiguchi S, et al. The association between vascular endothelial growth factorC, its corresponding receptor, VEGFR3, and prognosis in primary breast cancer: a study with 193 cases [Ｊ]. Oncol Rep, 2006; 15(3): 653659.
7.	Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)C and D and VEGF receptor 3 in invasive breast carcinoma [Ｊ]. Eur J Surg Oncol, 2007; 33(3): 294300.
8.	梁燕，姜軍，王清良，等. 自制組織芯片研究VEGFC在乳腺癌中的表達及其意義 [Ｊ]. 中國普外基礎與臨床雜志, 2006; 13(5): 580584.
9.	Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma [Ｊ]. Cancer, 2005; 103(4): 724730.
10.	Zhang XH, Huang D, Guo GL, et al. Coexpression of VEGFC and COX2 and its association with lymphangiogenesis in human breast cancer [Ｊ]. BMC Cancer, 2008; 8: 4.
11.	Siriwardena BS, Kudo Y, Ogawa I, et al. VEGFC is associated with lymphatic status and invasion in oral cancer [Ｊ]. J Clin Pathol, 2008; 61(1): 103108.
12.	Yavuz S, Paydas S, Disel U, et al. VEGFC expression in breast cancer: clinical importance [Ｊ]. Adv Ther, 2005; 22(4): 368380.
13.	Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER2/erbB2/cneu (HER2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 [Ｊ].Clin Cancer Res, 2001; 7(9): 27032711.
14.	Tanner M, Jrvinen P, Isola J. Amplification of HER2/neu and topoisomerase II in primary and metastatic breast cancer [Ｊ]. Cancer Res, 2001; 61(14): 53455348.
15.	Pienkowski T, Olszewski W, Kraszewakas E, et al. Predictive value of HER2 receptor, P53, bcl2 and bax proteins, MB1 antibody, estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen [Ｊ]. Eur J Cancer, 2002; 38(l3): 116119.
16.	蔡春友，付金瑞，劉妍菊，等. 乳腺癌NFkB HER2 VEGFC與VEGFR3表達及其意義 [Ｊ]. 中國腫瘤臨床, 2005; 32 (23): 13331337.

1. 李樹玲主編. 乳腺腫瘤學 [M]. 第1版. 北京：科學技術文獻出版社， 2000： 392393.
2. Birner P, Oberhuber G, Satni J, et al. Evaluation of the United States Food and Drug Administrationapproved scoring and test system of HER2 protein expression in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(6): 16691675.
3. Nathanson SD. Insights into the mechanisms of lymph node metastasis [Ｊ]. Cancer, 2003; 98(2): 413423.
4. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma：correlation with clinicopathologic parameters and VEGFfamily gene expression [Ｊ]. Mod Pathol, 2005; 18(1): 143152.
5. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factorCmediated lymphangiogenesis promotes tumour metastasis [Ｊ]. EMBO J, 2001; 20(4): 672682.
6. Bando H, Weich HA, Horiguchi S, et al. The association between vascular endothelial growth factorC, its corresponding receptor, VEGFR3, and prognosis in primary breast cancer: a study with 193 cases [Ｊ]. Oncol Rep, 2006; 15(3): 653659.
7. Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)C and D and VEGF receptor 3 in invasive breast carcinoma [Ｊ]. Eur J Surg Oncol, 2007; 33(3): 294300.
8. 梁燕，姜軍，王清良，等. 自制組織芯片研究VEGFC在乳腺癌中的表達及其意義 [Ｊ]. 中國普外基礎與臨床雜志, 2006; 13(5): 580584.
9. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma [Ｊ]. Cancer, 2005; 103(4): 724730.
10. Zhang XH, Huang D, Guo GL, et al. Coexpression of VEGFC and COX2 and its association with lymphangiogenesis in human breast cancer [Ｊ]. BMC Cancer, 2008; 8: 4.
11. Siriwardena BS, Kudo Y, Ogawa I, et al. VEGFC is associated with lymphatic status and invasion in oral cancer [Ｊ]. J Clin Pathol, 2008; 61(1): 103108.
12. Yavuz S, Paydas S, Disel U, et al. VEGFC expression in breast cancer: clinical importance [Ｊ]. Adv Ther, 2005; 22(4): 368380.
13. Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER2/erbB2/cneu (HER2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 [Ｊ].Clin Cancer Res, 2001; 7(9): 27032711.
14. Tanner M, Jrvinen P, Isola J. Amplification of HER2/neu and topoisomerase II in primary and metastatic breast cancer [Ｊ]. Cancer Res, 2001; 61(14): 53455348.
15. Pienkowski T, Olszewski W, Kraszewakas E, et al. Predictive value of HER2 receptor, P53, bcl2 and bax proteins, MB1 antibody, estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen [Ｊ]. Eur J Cancer, 2002; 38(l3): 116119.
16. 蔡春友，付金瑞，劉妍菊，等. 乳腺癌NFkB HER2 VEGFC與VEGFR3表達及其意義 [Ｊ]. 中國腫瘤臨床, 2005; 32 (23): 13331337.

《中國普外基礎與臨床雜志》

乳腺癌患者血清VEGF-C水平與癌組織C-erbB-2蛋白的表達及臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

乳腺癌患者血清VEGF-C水平與癌組織C-erbB-2蛋白的表達及臨床意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料